Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8733677 | Critical Reviews in Oncology/Hematology | 2018 | 24 Pages |
Abstract
The statistical methodology used to evaluate surrogate endpoints requires consistency in order to facilitate the accurate interpretation of the results. Despite the limited number of clinical settings with validated surrogate endpoints for OS, there is evidence of good surrogacy for DFS and PFS in tumor types that account for a large proportion of cancer cases.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Marion Savina, Sophie Gourgou, Antoine Italiano, Derek Dinart, Virginie Rondeau, Nicolas Penel, Simone Mathoulin-Pelissier, Carine Bellera,